Patient characteristics and OS for SEER cohorts 1 and 2
| Characteristics . | SEER cohort 1∗ (N = 57 783) . | SEER cohort 2† (N = 47 867) . |
|---|---|---|
| Age at diagnosis, median (range), y | 70 (18 to ≥100) | 70 (18-85) |
| Sex | ||
| Female | 22 922 (39.7) | 18 987 (39.7) |
| Male | 34 861 (60.3) | 28 880 (60.3) |
| Number of patients diagnosed per year, median (range) | ||
| 2009-2019 | 5 379 (4 100-5 620) | X |
| 2006-2016 | X | 4 462 (3 926-4 654) |
| Race | ||
| White | 50 515 (89.8) | 41 898 (90.4) |
| Black | 4 100 (7.3) | 3 267 (7.1) |
| Asian or Pacific Islander | 1 437 (2.6) | 1 052 (2.3) |
| American Indian/Alaska Native | 202 (0.4) | 143 (0.3) |
| Unknown | 1 529 | 1 507 |
| Ethnicity | ||
| Hispanic (all races) | 3 353 (5.8) | 2 428 (5.1) |
| Non-Hispanic White | 47 392 (82.0) | 39 627 (82.8) |
| Non-Hispanic Black | 4 050 (7.0) | 3 228 (6.7) |
| Non-Hispanic Asian or Pacific Islander | 1 415 (2.5) | 1 038 (2.2) |
| Non-Hispanic American Indian/Alaska Native | 188 (0.3) | 134 (0.3) |
| Non-Hispanic Unknown Race | 1 385 (2.4) | 1 412 (3.0) |
| Malignancy diagnosed before CLL | ||
| No | 45 543 (78.8) | X |
| Yes | 12 236 (21.2) | X |
| Unknown | 4 | X |
| Yost tertile | ||
| Group 1 | X | 11 118 (24.8) |
| Group 2 | X | 15 194 (33.8) |
| Group 3 | X | 18 609 (41.4) |
| Unknown | X | 2 946 |
| Rural-urban commuting area–based categorization | ||
| Rural | X | 4 055 (8.9) |
| Urban | X | 41 617 (91.1) |
| Unknown | X | 2 195 |
| OS | ||
| Number with follow-up data | 57 212 | 47 277 |
| Number of events | 16 987 | 15 053 |
| Median OS (95% CI), y | 9.8 (9.5-10) | 8.9 (8.7-9.0) |
| 1-y OS (95% CI) | 90.6 (90.4-90.9) | 89.7 (89.5-90.0) |
| 3-y OS (95% CI) | 79.8 (79.5-80.2) | 78.1 (77.7-78.5) |
| 5-y OS (95% CI) | 70.0 (69.5-70.4) | 67.3 (66.8-67.8) |
| 10-y OS (95% CI) | 48.9 (48.1-49.7) | 45.5 (44.6-46.3) |
| Median follow-up (range), y | 4.2 (0-10.9) | 4 (0-10.9) |
| Characteristics . | SEER cohort 1∗ (N = 57 783) . | SEER cohort 2† (N = 47 867) . |
|---|---|---|
| Age at diagnosis, median (range), y | 70 (18 to ≥100) | 70 (18-85) |
| Sex | ||
| Female | 22 922 (39.7) | 18 987 (39.7) |
| Male | 34 861 (60.3) | 28 880 (60.3) |
| Number of patients diagnosed per year, median (range) | ||
| 2009-2019 | 5 379 (4 100-5 620) | X |
| 2006-2016 | X | 4 462 (3 926-4 654) |
| Race | ||
| White | 50 515 (89.8) | 41 898 (90.4) |
| Black | 4 100 (7.3) | 3 267 (7.1) |
| Asian or Pacific Islander | 1 437 (2.6) | 1 052 (2.3) |
| American Indian/Alaska Native | 202 (0.4) | 143 (0.3) |
| Unknown | 1 529 | 1 507 |
| Ethnicity | ||
| Hispanic (all races) | 3 353 (5.8) | 2 428 (5.1) |
| Non-Hispanic White | 47 392 (82.0) | 39 627 (82.8) |
| Non-Hispanic Black | 4 050 (7.0) | 3 228 (6.7) |
| Non-Hispanic Asian or Pacific Islander | 1 415 (2.5) | 1 038 (2.2) |
| Non-Hispanic American Indian/Alaska Native | 188 (0.3) | 134 (0.3) |
| Non-Hispanic Unknown Race | 1 385 (2.4) | 1 412 (3.0) |
| Malignancy diagnosed before CLL | ||
| No | 45 543 (78.8) | X |
| Yes | 12 236 (21.2) | X |
| Unknown | 4 | X |
| Yost tertile | ||
| Group 1 | X | 11 118 (24.8) |
| Group 2 | X | 15 194 (33.8) |
| Group 3 | X | 18 609 (41.4) |
| Unknown | X | 2 946 |
| Rural-urban commuting area–based categorization | ||
| Rural | X | 4 055 (8.9) |
| Urban | X | 41 617 (91.1) |
| Unknown | X | 2 195 |
| OS | ||
| Number with follow-up data | 57 212 | 47 277 |
| Number of events | 16 987 | 15 053 |
| Median OS (95% CI), y | 9.8 (9.5-10) | 8.9 (8.7-9.0) |
| 1-y OS (95% CI) | 90.6 (90.4-90.9) | 89.7 (89.5-90.0) |
| 3-y OS (95% CI) | 79.8 (79.5-80.2) | 78.1 (77.7-78.5) |
| 5-y OS (95% CI) | 70.0 (69.5-70.4) | 67.3 (66.8-67.8) |
| 10-y OS (95% CI) | 48.9 (48.1-49.7) | 45.5 (44.6-46.3) |
| Median follow-up (range), y | 4.2 (0-10.9) | 4 (0-10.9) |
X, not assessed in this cohort.
SEER Program (www.seer.cancer.gov) SEER∗Stat Database: Incidence-SEER Research Plus Data, 17 Registries, Nov 2021 Sub (2000-2019)-Linked To County Attributes-Time Dependent (1990-2019) Income/Rurality, 1969 to 2020 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2022, based on the November 2021 submission.
SEER Program (www.seer.cancer.gov) SEER∗Stat Database: Incidence-SEER 18 Regs (Excl AK) Custom Data (with additional treatment fields), Nov 2018 Sub (2000-2016) <Vintage 2016 Pops by Tract 2000/2010 Mixed Geographies> - Linked To Census Tract Attributes-Time Dependent (2000-2016) - SEER 18 (excl AK) Census 2000/2010 Geographies with Index Field Quantiles, National Cancer Institute, DCCPS, Surveillance Research Program, released January 2020, based on the November 2018 submission.